The Zhitong Finance App learned that AstraZeneca (AZN.US) announced that it has reached a cooperation with machine learning biotechnology company Insitro totaling up to 1.86 billion US dollars to help the British pharmaceutical company find new drugs for liver and heart diseases. AstraZeneca said on Thursday it will make a $40 million down payment. Insitro will combine its own data with AstraZeneca data to better understand the causes of fatty liver disease and myocardial disease. If this path works, the biotech company could receive up to $1.46 billion in additional payments, as well as a potential share of sales.

The Zhitong Finance App learned that AstraZeneca (AZN.US) announced that it has reached a cooperation with machine learning biotechnology company Insitro totaling up to 1.86 billion US dollars to help the British pharmaceutical company find new drugs for liver and heart diseases. AstraZeneca said on Thursday it will make a $40 million down payment. Insitro will combine its own data with AstraZeneca data to better understand the causes of fatty liver disease and myocardial disease. If this path works, the biotech company could receive up to $1.46 billion in additional payments, as well as a potential share of sales.